Sanofi India Ltd — Investor Presentation 2024

May 16, 2024

==> picture [111 x 29] intentionally omitted <==

16[th] May 2024

The Secretary The Secretary BSE Limited The National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers Exchange Plaza, 5[th] Floor Dalal Street, Mumbai - 400 001 Plot No. C/1, G Block Scrip Code: 500674 Bandra-Kurla Complex, Bandra East Mumbai - 400 050 Symbol: SANOFI

Sub: Outcome of Investor / Analysts Call

Dear Sirs,

We refer to our letter dated 7[th] May 2024, informing you of our Investor / Analysts call scheduled today i.e., 16[th] May 2024 at 2:00 p.m.

In this regard and pursuant to Regulation 30 read with Part A of Schedule Ill of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the presentation made to the Investors / Analysts Call and the same is also being uploaded on the website of the Company. The recording and transcript of the Call thereof will be submitted to Stock Exchanges in due course and simultaneously be uploaded on the website of the Company at Analyst / Investor Meet (sanofiindialtd.com)

Kindly take the above information on record.

Yours faithfully

For Sanofi India Limited

RADHIKA Digitally signed by RADHIKA KARTIK SHAH KARTIK SHAH Date: 2024.05.16 16:22:34 +05'30'

Radhika Shah

Company Secretary & Compliance Officer Membership No: A19308

Sanofi India Limited, Sanofi House, CTS No. 117-B, L&T Business Park, Saki Vihar Road, Powai, Mumbai 400 072 - India - Tel.: +91(22) 2803 2000 - Fax: +91(22) 2803 2939 Corporate Identity Number: L24239MH1956PLC009794 Website: www.sanofiindialtd.com | www.sanofi.in Email: igrc.sil@sanofi.com

==> picture [502 x 540] intentionally omitted <==

Investor PresentationQ1’24 Update May 16, 2024

Disclaimer

This Release / Communication, except for the historical information, may contain statements, including the words or phrases such as expects, anticipates, intends, will, would, undertakes, aims, estimates, contemplates, seeks to, objective, goal, projects, should and similar expressions or variations of these expressions or negatives of these terms indicating future performance or results, financial or otherwise, which are forward looking statements. These forward looking statements are based on certain expectations, assumptions, anticipated developments and other factors which are not limited to, risk and uncertainties regarding fluctuations in earnings, market growth, competition and the pricing environment in the market, customer relationship and supply chain sources and those factors which may affect our ability to implement business strategies successfully, namely changes in regulatory environments, geopolitical stability, costs etc. The Company, therefore, cannot guarantee that the forward-looking statements made herein shall be realized. The Company, based on changes as stated above, may alter, amend, modify or make necessary corrective changes in any manner to any such forward looking statement contained herein or make written.

Internal

A quick update on India for India pillars

Diabetes Consumer Healthcare E2E Innovation GTM HCP reach expansion Double down on winning Fully leverage local Strengthen reach (Customer centric and brand: Allegra Innovation hybrid) Deployment of trade Expand spectrum Deeper consumer Localize supply organization (Retail and offering understanding non-retail) Public disease and Pilot transformation Partnerships for reach therapy awareness Shape OTC policy models (ecommerce, on EP Initiative HCP, e-KAM) • From 8 to 3 Bus. • Volume acceleration of Lantus • Governance on track for demerger

• Deployed Trade Organization

• Insutage (May’24) , Cetapin S (May’24)

• Organizational readiness

==> picture [94 x 33] intentionally omitted <==

==> picture [96 x 35] intentionally omitted <==

• SOLIQUA

==> picture [148 x 27] intentionally omitted <==

3

Internal

Delivering through careful choice of strategic partnerships for reach on EP

==> picture [415 x 168] intentionally omitted <==

==> picture [473 x 168] intentionally omitted <==

• • Depakote®, Valparin®, Frisium® , Stilnoct® , Vinlep® and Cardace®, Clexane®, Targocid®, Lasix® and Lasilactone® Solian®

• Other CV brands from Sanofi Pvt • Other CNS brands from Sanofi Pvt

4

Internal

New Product Launches are on Track

==> picture [67 x 45] intentionally omitted <==

==> picture [902 x 373] intentionally omitted <==

----- Start of picture text -----

Allegra
Nasal spray
2025
Oct 23
2024
Dec 23
----- End of picture text -----

Internal

Soliqua - Customers, Positioning and Key messaging

==> picture [161 x 139] intentionally omitted <==

• Endocrinologist and specialist in Internal Medicine

==> picture [207 x 162] intentionally omitted <==

• 2 Key patient segments

• OAD Uncontrolled patients

• Basal Intensification patients

Soliqua relieves treatment burden & helps break the complexity of living with T2DM

==> picture [127 x 126] intentionally omitted <==

Reduced risk of hypoglycemia

(vs intensified insulin regimes)

==> picture [126 x 126] intentionally omitted <==

Weight benefits

(vs intensified insulin regimes)

==> picture [126 x 126] intentionally omitted <==

Single touch a day

6

INTERNAL USE

Internal

Sanofi’s India For India is a loud call ….

==> picture [350 x 313] intentionally omitted <==

==> picture [355 x 176] intentionally omitted <==

7

Internal

Key Highlights: Non comparable quarters Q1/24 Vs Q1/23

 NLEM implementation in April 2023 still impacting the top-line performance in Q1/24 Vs last year. No price impact starting April 2024.

• Strong Q1/23 export with +30% growth mainly volume and favorable FX

• Other income Q1/23 : increase thanks to interest on banks deposit before the dividend distribution

• & one-off interest on income tax refund in Q1/23

• High profit before exceptional items and tax in Q1/23 which was one of the highest quarterly profit in

17 quarters (Please refer to Last year investors call)

• Exceptional items in Q1/23 mainly related to the sales of assets (18Cr)

• Strategic partnership with Emcure and Cipla end of Q1/24 for CV portfolio and CNS leading to downsizing of the team and the payment of severance package (Exceptional items:27 cr)

₹ in Cr.

Internal

Retained domestic Sales and Profit Before excep. items & Tax Q1/24 Vs Q1/23 & Q1/23 Retained= Excluding mainly Soframycin divestment

Comparable= Excluding Lantus NLEM price decrease and exceptional items (Restructuring)

==> picture [352 x 285] intentionally omitted <==

----- Start of picture text -----

+ 3%
+8% Comp
548 566
-1 2%
5487 5655 246 215
2457
2151
Q1 23 Q1 24 Q1 23 Q1 24
Domestic Retained Sales PBT & excep items
----- End of picture text -----

==> picture [342 x 287] intentionally omitted <==

----- Start of picture text -----

+8%
522 566
+14%
215
189
Q4 23 Q1 24 Q4 23 Q1 24
Domestic Retained Sales PBT & excep items
----- End of picture text -----

• Q1/24 sales: +1% Vs Q1/23

• Retained business (mainly excluding Soframycin divest) +3%

• Excluding NLEM price decrease, retained business would grow by 8%

• Largely comparable quarter where Retained domestic sales grew by + 8%

• Continuous effort on efficiency with flat OPEX aligned with India for India strategy

• As a result, we have 14% growth in the PBT & exceptional items

• Continuous effort on efficiency with flat OPEX aligned with India for India strategy

• Exceptional items for Q1/24 are related to the restructuring cost

• As a result, PBT & exceptional items degrow by 12 %

• due to elements mentioned in the key highlight

Internal

₹ in Cr.

Consistent Increase in

Profit Before excep items & tax both in terms of absolute value & % to sales

==> picture [835 x 290] intentionally omitted <==

----- Start of picture text -----

Abs value Abs %
300 40%
36%
246 35%
250 31% 31% 32%
29%
208 215 210 30% 28% 28% 28%
26%
200 183 182 189
176 25%
166
150 20%
15%
100
10%
50
5%
0 0%
Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4
2022 2023 2024 2022 2023 2024
----- End of picture text -----

• Steady growth from one quarter to another

• Profit before exceptional items & tax Q1/24 remains high Vs the other quarter (Excluding the exceptional Q1/23)

Internal

CHC Sales and operating Profit Q1/24:

Q1.24 Total Sales

==> picture [375 x 318] intentionally omitted <==

----- Start of picture text -----

30%
70%
GEM CHC
----- End of picture text -----

Q1.24 Operating Profit

==> picture [370 x 318] intentionally omitted <==

----- Start of picture text -----

37%-39%
GEM CHC
----- End of picture text -----

Disclaimer:

• These are indicative and not audited

• CHC numbers will be disclosed when SCHIL will be listed, and financial statements are audited

Internal

CHC – Transitioning towards establishing a strong FMCH company

==> picture [5 x 4] intentionally omitted <==

Business plan growth levers

==> picture [5 x 4] intentionally omitted <==

Upsides beyond plans

Accelerate growth

==> picture [182 x 63] intentionally omitted <==

Enhance CHC portfolio

• Increase market penetration

• Shape Modern OTC regulations

Build consumer centric

mindset

• Deepen affinity with consumer

• Drive awareness and accelerate love brands

Best in class digital / e- commerce capabilities

• Step up e-commerce

• Build world class digital marketing

• Fully leverage global CHC data and digital edge

• Explore opportunities to grow inorganically

• Direct To Consumer brand activation

• Enhance presence in

• Innovation channels like modern trade

Internal

Strong in market performance across brands in Q1’24. CHC brands continue to gain share in spite of the market slowdown

==> picture [628 x 298] intentionally omitted <==

----- Start of picture text -----

Category Allergy Physical Wellness
 Category growth +1%  Category growth +4%
In Market
 CHC Brand growth +9%  CHC Brand growth +20%
Performance
Qtr 1 2024  Delta vs mkt +8.2%  Delta vs mkt +16.3%
Key SKUs
----- End of picture text -----

==> picture [243 x 47] intentionally omitted <==

----- Start of picture text -----

Pain Care
----- End of picture text -----

==> picture [243 x 97] intentionally omitted <==

----- Start of picture text -----

 Category growth +1%
 CHC Brand growth +19%
 Delta vs mkt +17.8%
----- End of picture text -----

==> picture [45 x 96] intentionally omitted <==

==> picture [140 x 84] intentionally omitted <==

Source – IQVIA

==> picture [504 x 540] intentionally omitted <==

Thank You